NCT02661893View on ClinicalTrials.gov

A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Healthy
Interventions
DRUG

JNJ-42847922

A single oral dose of 40 milligram (mg) (=2\*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.

DRUG

Rifampin

Oral dose of rifampin 600 mg (2\*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2\*300 mg) on Days 5 to 12.

Trial Locations (1)

Unknown

Overland Park

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02661893 - A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922 | Biotech Hunter | Biotech Hunter